Holen Sie sich die Stockscreener-App
2.255
2.04%
0.045
Schlusskurs vom Vortag:
$2.21
Offen:
$2.22
24-Stunden-Volumen:
185.12K
Relative Volume:
0.43
Marktkapitalisierung:
$212.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$1.60M
KGV:
75.17
EPS:
0.03
Netto-Cashflow:
$-62.91M
1W Leistung:
+8.41%
1M Leistung:
+36.67%
6M Leistung:
+68.28%
1J Leistung:
+40.06%
1-Tages-Spanne:
$2.22
$2.35
1-Wochen-Bereich:
$2.03
$2.35
52-Wochen-Spanne:
$1.13
$2.38
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.25 | 208.96M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.22 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.63 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.02 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.96 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.43 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-26 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-05-13 | Eingeleitet | Stifel | Buy |
| 2020-05-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-04-22 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-03-29 | Eingeleitet | Oppenheimer | Outperform |
| 2016-02-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2015-10-15 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-23 | Fortgesetzt | Jefferies | Buy |
| 2015-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2014-02-07 | Eingeleitet | MLV & Co | Buy |
| 2009-12-28 | Bestätigt | Cantor Fitzgerald | Buy |
| 2009-07-29 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Compugen Ltd Aktie (CGEN) Neueste Nachrichten
Compugen Ltd. (CGEN) Reports Q4 Revenue of $67.3 Million vs. $1.5 Million Last Year - Insider Monkey
Compugen (CGEN) Q4 2025 Earnings Call Transcript - AOL.com
Compugen at Leerink Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com Australia
Compugen at Leerink Global Healthcare Conference: Strategic Insights - Investing.com South Africa
Short Squeeze: Is Compugen Ltd stock forming a triangle pattern2026 PreEarnings & Consistent Growth Stock Picks - baoquankhu1.vn
Q1 Earnings Estimate for Compugen Issued By HC Wainwright - Defense World
BillionToOne Stock at $89: Why a New $19.1 Million Position Could Matter Now - AOL.com
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - AOL.com
Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Compugen Q4 Earnings Call Highlights - Defense World
Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings - AOL.com
Cumberland (CPIX) Q4 2025 Earnings Call Transcript - AOL.com
Compugen Ltd. (NASDAQ:CGEN) Q4 2025 Earnings Call Transcript - Insider Monkey
Compugen (CGEN) Quarterly Loss Near US$7 Million Tests Bullish Profitability Narrative - simplywall.st
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing - AOL.com
Compugen earnings beat by $0.68, revenue topped estimates - Investing.com South Africa
Chegg Earnings: Big Quarter Sends Shares Higher - AOL.com
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement (CGEN) - Seeking Alpha
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Compugen Q4 2025 Earnings Call Transcript - MarketBeat
Compugen Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
What Smart Money Loves About Lilly - AOL.com
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Earnings call transcript: Compugen Q4 2025 sees earnings beat, stock surges - Investing.com
CGEN: 2025 saw a cash runway extension, profitability, and global clinical trial progress - TradingView
Compugen Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
CGEN: 2025 saw strong revenue growth, a return to profitability, and extended cash runway into 2029 - TradingView
Compugen: Overview of Fourth Quarter Financial Results - Bitget
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Compugen Extends Cash Runway to 2029 and Swings to Profit on AstraZeneca Deal and Clinical Progress - TipRanks
Partnership payments lift Compugen (NASDAQ: CGEN) to 2025 profit - Stock Titan
COMPUGEN ($CGEN) Releases Q4 2025 Earnings - Quiver Quantitative
Compugen stock jumps 5% on fourth quarter earnings beat By Investing.com - Investing.com India
Compugen stock jumps 5% on fourth quarter earnings beat - Investing.com
Compugen: Q4 Earnings Snapshot - marketscreener.com
Compugen : Corporate Presentation - marketscreener.com
Earnings Breakdown: Compugen Q4 - Benzinga
CGEN: Profitability achieved in 2025, driven by AstraZeneca deal and robust clinical progress - TradingView
Compugen (Nasdaq: CGEN) swings to 2025 profit, extends cash runway to 2029 - Stock Titan
Compugen Reports Fourth Quarter and Full Year 2025 Results - Yahoo Finance
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - AOL.com
Uncovering Potential: Compugen's Earnings Preview - Benzinga
Compugen Ltd expected to post earnings of 5 cents a shareEarnings Preview - TradingView
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition - AOL.com
Compugen Ltd (CGEN) Q4 2025: Everything You Need To Know Ahead O - GuruFocus
MSN Money - MSN
Compugen CEO Highlights COM701 Ovarian Cancer MAIA Trial, AstraZeneca and Gilead Updates at Oppenheimer Conf - Defense World
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% - AOL.com
Compugen at Oppenheimer Conference: Strategic Insights on Partnerships - Investing.com South Africa
Finanzdaten der Compugen Ltd-Aktie (CGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):